Norges Bank’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-328,067
| Closed | -$104M | – | 1986 |
|
|
2023
Q4 | $104M | Sell |
328,067
-2,002
| -0.6% | -$389K | 0.02% | 587 |
|
|
2023
Q3 | $55.8M | Buy |
330,069
+53,358
| +19% | +$10M | 0.01% | 780 |
|
|
2023
Q2 | $60M | Sell |
276,711
-69,233
| -20% | -$14.8M | 0.01% | 772 |
|
|
2023
Q1 | $62.8M | Buy |
345,944
+34,459
| +11% | +$6.59M | 0.01% | 732 |
|
|
2022
Q4 | $61.2M | Buy |
311,485
+50,376
| +19% | +$10.8M | 0.01% | 718 |
|
|
2022
Q3 | $58.7M | Buy |
261,109
+63,436
| +32% | +$12.8M | 0.02% | 691 |
|
|
2022
Q2 | $25M | Sell |
197,673
-989
| -0.5% | -$114K | 0.01% | 1134 |
|
|
2022
Q1 | $25.2M | Sell |
198,662
-14,200
| -7% | -$1.6M | 0.01% | 1275 |
|
|
2021
Q4 | $27.9M | Buy |
212,862
+29,222
| +16% | +$3.78M | 0.01% | 1281 |
|
|
2021
Q3 | $22.5M | Buy |
183,640
+22,731
| +14% | +$2.62M | 0.01% | 1418 |
|
|
2021
Q2 | $18.3M | Buy |
160,909
+86,495
| +116% | +$10.1M | ﹤0.01% | 1577 |
|
|
2021
Q1 | $8.95M | Sell |
74,414
-104,893
| -58% | -$11.9M | ﹤0.01% | 1814 |
|
|
2020
Q4 | $18.2M | Buy |
179,307
+3,213
| +2% | +$298K | ﹤0.01% | 1589 |
|
|
2020
Q3 | $13.6M | Buy |
+176,094
| New | +$15M | ﹤0.01% | 1615 |
|
|
2019
Q3 | – | Sell |
-10,000
| Closed | -$200K | – | 2116 |
|
|
2019
Q2 | $200K | Buy |
+10,000
| New | +$200K | ﹤0.01% | 2079 |
|
Other funds holding KRTX
Norges Bank's KRTX Position: Q1 2024 in Review
Norges Bank sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 328,067 shares — an estimated $104M sold.
Norges Bank first reported a position in KRTX in Q2 2019 and held it in 15 quarters. The position peaked at $104M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.
- Norges Bank reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Norges Bank sold 328,067 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $104M.
- Norges Bank first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 15 quarters.
- Norges Bank's Karuna Therapeutics, Inc. Common Stock position peaked at $104M in Q4 2023.
- 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Norges Bank's 13F filing for Q1 2024, filed 14 May 2024.